Related Experiment Video
Updated: Mar 14, 2026
Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
Published on: March 2, 2020
A new selective fluorescent probe based on tamoxifen
Louisa A Ho1, Elizabeth Thomas2, Robert A McLaughlin3
1School of Chemistry and Biochemistry M310, The University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia.
Abstract:
Developing targeted validation probes that can interrogate biology is of interest for both chemists and biologists. The synthesis of suitable compounds provides a means for avoiding the costly labeling of cells with specific antibodies and the bias associated with the interpretation of biological validation experiments. The chemotherapeutic agent, tamoxifen has been routinely used in the treatment of breast cancer for decades. Once metabolized, the active form of tamoxifen (4-hydroxytamoxifen) competes with the binding of estrogens to the estrogen receptors (ER). Its selectivity in ER modulation makes it an ideal candidate for the development of materials to be used as chemical probes. Here we report the synthesis of a fluorescent BODIPY®FL conjugate of tamoxifen linked through an ethylene glycol moiety, and present proof-of-principle results in ER positive and ER negative cell lines. Optical microscopy indicates that the fluorescent probe binds selectively to tamoxifen sensitive breast cancer cell lines. The compound showed no affinity for the tamoxifen resistant breast cancer lines. The specificity of the new compound make it a valuable addition to the chemical probe tool kit for estrogen receptors.
Insights
Researchers developed a new fluorescent tamoxifen probe to study estrogen receptors in breast cancer. This chemical probe selectively binds to tamoxifen-sensitive cells, aiding biological validation without costly antibody labeling.
Area of Science:
- Chemical Biology
- Molecular Biology
- Cancer Research
Background:
- Developing targeted validation probes is crucial for biological interrogation, offering an alternative to antibody labeling and reducing experimental bias.
- Tamoxifen, a widely used breast cancer chemotherapeutic, and its active metabolite 4-hydroxytamoxifen, selectively modulate estrogen receptors (ER).
Purpose of the Study:
- To synthesize a fluorescent BODIPY®FL conjugate of tamoxifen for use as a chemical probe.
- To evaluate the probe's specificity and binding affinity in estrogen receptor-positive and -negative breast cancer cell lines.
Main Methods:
- Synthesis of a fluorescent tamoxifen-BODIPY®FL conjugate linked via an ethylene glycol moiety.
- Assessment of probe binding using optical microscopy in ER-positive and ER-negative cell lines, including tamoxifen-resistant variants.
Main Results:
- The synthesized fluorescent tamoxifen probe demonstrated selective binding to tamoxifen-sensitive ER-positive breast cancer cells.
- No significant affinity was observed for tamoxifen-resistant breast cancer cell lines, indicating high specificity.
Conclusions:
- The novel fluorescent tamoxifen probe is a valuable tool for estrogen receptor research.
- This chemical probe facilitates targeted biological validation in breast cancer studies, offering specificity and avoiding limitations of traditional methods.
